Flamel Tech acquires US firm Eclat Pharma; reports loss

Lyon, France-based drug delivery firm Flamel Technologies (Nasdaq: FLML) said last week that it has acquired Eclat Pharmaceuticals, a US specialty pharmaceutical company that is focused on the development, approval, and commercialization of niche brands and generic products.

Prior to the buy, Eclat was an affiliate of Deerfield Capital which, together with its other affiliates, is Flamel’s largest shareholder.

Eclat has one approved product on the market, the prescription analgesic Hycet (hydrocodone acetaminophen oral solution), as well as a suite of products in various stages of development. Eclat’s founder and chief executive Mike Anderson will become CEO of Flamel, as Steve Willard resigns from that post though remaining on the company’s board of directors.